Can mometasone furoate nasal spray be used concomitantly with azelastine nasal spray?

Can Mometasone Furoate and Azelastine Nasal Sprays Be Used Together?

Yes, mometasone furoate nasal spray can be safely and effectively used concomitantly with azelastine nasal spray, and this combination is actually recommended for moderate to severe allergic rhinitis in patients aged 12 years or older.

Guideline-Based Recommendation

The 2017 Joint Task Force on Practice Parameters explicitly supports combining an intranasal corticosteroid (like mometasone furoate) with an intranasal antihistamine (like azelastine) for initial treatment of moderate to severe seasonal allergic rhinitis 1. While this is a weak recommendation due to cost and potential for additional side effects, the clinical evidence demonstrates meaningful symptom improvement.

Key Evidence Supporting Combination Therapy

The combination provides superior symptom control compared to either agent alone:

• Five clinical trials demonstrated that intranasal corticosteroid plus azelastine combination therapy achieved the greatest symptom reduction, followed by corticosteroid alone, then azelastine alone, then placebo 1
• Symptom score reductions showed approximately 40% greater relative improvement with combination therapy versus monotherapy 1
• Real-world evidence from the MASK study (9,122 users, 112,054 days of data) confirmed that combination therapy resulted in better disease control 2

How to Use the Combination

Administration approach:

• Both medications can be administered using separate commercially available sprays 1
• No drug interaction concerns exist between these two agents based on FDA labeling 3, 4
• The combination works synergistically by suppressing both Th2 and Th17 inflammatory responses while elevating regulatory T-cell responses 5

Safety Profile

The combination is well-tolerated:

• Adverse event rates are low across all studies 1
• Dysgeusia (altered taste) is the most common side effect (2.1-13.5% of patients), occurring more frequently with azelastine-containing regimens 1
• Epistaxis rates are similar to or lower than placebo 1
• Somnolence occurs in only 0.4-1.1% of patients using azelastine 1

Important Caveats

Counsel patients about:

• Potential for bitter taste, especially with azelastine—this is the primary reason for discontinuation
• Avoiding concurrent use of azelastine with alcohol or CNS depressants due to additive sedation risk 4
• Assessing individual response before driving or operating machinery when first starting azelastine 4

Clinical Decision Algorithm

For patients aged 12 years or older with allergic rhinitis:

1. Mild symptoms: Start with intranasal corticosteroid (mometasone) alone
2. Moderate to severe symptoms: Consider combination therapy from the start 1
3. Inadequate response to monotherapy: Add the second agent

For children aged 2-11 years:

• Both medications are approved for this age group individually 3, 4
• Evidence for combination therapy is limited to ages 12+, but both can be used separately in younger children

Real-World Performance

Research studies specifically examining mometasone furoate combined with azelastine demonstrate:

• More pronounced alleviation of rhinological symptoms at early treatment stages compared to monotherapy 6
• Effective for both seasonal and perennial allergic rhinitis 7, 8, 9
• Patients using combination therapy require less additional comedication compared to those on corticosteroids alone 2

Bottom line: This is an evidence-based, guideline-supported combination that provides clinically meaningful benefit for patients with moderate to severe allergic rhinitis, with an acceptable safety profile when patients are counseled about potential taste disturbance and rare sedation.